NBIO — Nascent Biotech Income Statement
0.000.00%
Last trade - 00:00- $0.50m
- $0.51m
Annual income statement for Nascent Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.75 | 1 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.45 | 2 | 1.45 | 2.13 | 2.18 |
| Operating Profit | -3.45 | -1.25 | -0.452 | -2.13 | -2.18 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4 | -0.959 | -0.47 | -2.8 | -2.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4 | -0.959 | -0.47 | -2.8 | -2.09 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4 | -0.959 | -0.47 | -2.8 | -2.09 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4 | -0.959 | -0.47 | -2.8 | -2.09 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.116 | -0.015 | -0.004 | -0.024 | -0.014 |